Trials / Recruiting
RecruitingNCT06834035
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- M. Peter Marinkovich · Academic / Other
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Conditions
- Epidermolysis Bullosa
- Epidermolysis Bullosa Acquisita
- Dystrophic Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunoglobulin G | Purified IgG from human serum, delivered via IV |
Timeline
- Start date
- 2025-08-04
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2025-02-19
- Last updated
- 2026-03-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06834035. Inclusion in this directory is not an endorsement.